Agent | Company | Injection route | Volume | Concentration (Vehicle) | Time of administration | Time of sacrifice | n of mice |
---|---|---|---|---|---|---|---|
Tissue plasminogen activator (tPA) | Actilyse; INN alteplase, Boehringer Ingelheim, Germany | Tail vein | 50 μl/min (1 min) + 15 μl/min (30–60 min) | 10 mg/kg | 1 h after ischemia | 30–60 min after tPA injection | 17 |
Dextran (FITC–70S or/and TRITC–500S) | Sigma | Tail vein | 0.2 ml | 5 mg/ml (saline) | 1 h before ischemia and 1 h after tPA injection | 1 h after ischemia/recanalisation | 34 |
Adenosine | Molecular Probes | Intravitreal | 3 μl | 1 mg/ml (water) | Just before ischemia | 1 h after ischemia | 4 |
1 h after ischemia | 2 h after ischemia | 3 | |||||
Amlodipine | Pfizer | Intravitreal | 3 μl | 1 mg/ml (water) | 1 h before ischemia | 1 h after ischemia | 3 |
Carbenoxolone (CBX) | Sigma | Intravitreal | 3 μl | 30 μM (water) | Just before ischemia | 1 h after ischemia | 4 |
Fluorescent phalloidin | Biotium | Intravitreal | 3 μl | 200 U/ml (water) | 1–2 h before ischemia | 1 h after ischemia | 5 |
Propidium iodide (PI) | Molecular Probes, Invitrogen | Intravitreal | 1 μl | 1 mg/ml (water) | 1 h after ischemia | 4–6 h after ischemia | 5 |
Tissue plasminogen activator (tPA) + Fluorescent phalloidin | Actilyse; INN alteplase, Boehringer Ingelheim, Germany; Biotium | Tail vein Intravitreal | 50 μl/min (1 min) + 15 μl/min (30–60 min) 3 μl | 10 mg/kg 200 U/ml (water) | 1 h after ischemia 30 min after ischemia | 1 h after tPA injection | 6 |
Fluo-4 | Molecular Probes, Invitrogen | Intravitreal | 3 μl | 5 μM (0.005% pluronic acid, 0.00025% cremophor and 0.05% DMSO in artificial CSF) | Just before ischemia | 2 h after ischemia | 18 |
Scrambled peptide | Smart-Bioscience | Intravitreal | 2 μl | 20 μM (nuclease free water) | 1 h before ischemia | 1 h after ischemia | 6 |
Peptide | Smart-Bioscience | Intravitreal | 2 μl | 20 μM (nuclease free water) | 1 h before ischemia | 1 h after ischemia | 6 |
1,4-Dideoxy-1,4-imino-D-arabinitol hydrochloride (DAB) | Sigma-Aldrich | Intravitreal | 3 μl | 2.5 M (saline) | 2 h before ischemia | 30 min after ischemia | 9 |
Scrambled siRNA | Ambion® LifeTech, | Intravitreal | 3 μl | 0.5 mg/ml (10% Glucose, nuclease free wáter, in~vivo-jetPEI®, 10% Glucose) | 48 h before ischemia | 1 h after ischemia | 3 |
α SMA siRNA | Ambion® LifeTech, | Intravitreal | 3 μl | 0.5 mg/ml (10% Glucose, nuclease free wáter, in~vivo-jetPEI®, 10% Glucose) | 48 h before ischemia | 1 h after ischemia | 3 |